Generics, so long the force that has shaken up the branded pharmaceutical industry, is now facing its own challenges as an industry. While growth indications are strong, there are challenges for generic companies. In the next two years, consolidation will most likely rise; the sector is expected to be rocked by increased competition from companies in Eastern Europe, India and China, as well as brand name companies seeking to protect their franchises by moving into generics.
Kalorama Information's World Market for Prescription Generic Drugs, 6th Edition is your guide to this formidable and important participant in the complex world of healthcare. Included are market size and forecast revnues for:
Allergy and Respiaratory Drugs
Analgesics, NAIDS, and Antirheumatic Drugs
Central Nervous System and Psychotherapeutic Drugs
This report is the result of primary research and secondary research. Interviews with experts in the generic industry form the basis of this report. Research was conducted from available company reports, trade publications and medical and government databases. Interviews with experts are the source of models.
For each drug segment, the report provides:
Estimated Generic Market Size
Forecast to 2012
Recent ANDA Approvals
World and US Market Share
Knowledge of the issues that face the generics industry is essential to understanding the market. The report discusses the following trends:
Big Pharma Tactics
Medicaid Generic Drug Reimbursement
Confusion in Generic Names
Broadening Generic Horizons
International Generic Drug Issues
Indian Drug Makers
New Generic Giants
Generic Companies Increasingly Aggressive
Generics Improve Compliance
Generic Drug Sampling
Marketing executives, business development managers and brand and generic pharmaceutical companies, consultants and investors are among those who will benefit from this report.